Connection

DIHUA YU to Tumor Cells, Cultured

This is a "connection" page, showing publications DIHUA YU has written about Tumor Cells, Cultured.
Connection Strength

0.412
  1. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Res. 2014 May; 24(5):542-59.
    View in: PubMed
    Score: 0.068
  2. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 2001 Dec 06; 20(56):8066-74.
    View in: PubMed
    Score: 0.029
  3. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Res. 1999 Apr 01; 59(7):1620-5.
    View in: PubMed
    Score: 0.024
  4. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell. 1998 Nov; 2(5):581-91.
    View in: PubMed
    Score: 0.023
  5. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res. 1998 Aug; 4(8):1985-94.
    View in: PubMed
    Score: 0.023
  6. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998 Apr 23; 16(16):2087-94.
    View in: PubMed
    Score: 0.023
  7. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1) J Natl Cancer Inst. 1997 Oct 15; 89(20):1524-9.
    View in: PubMed
    Score: 0.022
  8. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017 10 01; 77(19):5374-5383.
    View in: PubMed
    Score: 0.022
  9. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996 Sep 19; 13(6):1359-65.
    View in: PubMed
    Score: 0.020
  10. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene. 1996 May 02; 12(9):2035-9.
    View in: PubMed
    Score: 0.020
  11. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. 1995 Oct 05; 11(7):1383-8.
    View in: PubMed
    Score: 0.019
  12. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993 Feb 15; 53(4):891-8.
    View in: PubMed
    Score: 0.016
  13. Localizing the EGF receptor. Nat Cell Biol. 2002 Feb; 4(2):E22; author reply E22-3.
    View in: PubMed
    Score: 0.015
  14. Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene. 1991 Nov; 6(11):1991-6.
    View in: PubMed
    Score: 0.014
  15. Transcriptional upregulation and activation of p55Cdc via p34(cdc2) in Taxol-induced apoptosis. Oncogene. 2001 May 03; 20(20):2537-43.
    View in: PubMed
    Score: 0.007
  16. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene. 2000 Oct 05; 19(42):4864-75.
    View in: PubMed
    Score: 0.007
  17. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000 Jul 01; 60(13):3655-61.
    View in: PubMed
    Score: 0.007
  18. Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 2000 Mar; 7(3):422-9.
    View in: PubMed
    Score: 0.006
  19. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res. 2000 Jan; 6(1):250-9.
    View in: PubMed
    Score: 0.006
  20. Inhibition of the transcription factor nuclear factor-kappa B by adenoviral-mediated expression of I kappa B alpha M results in tumor cell death. Surgery. 1999 Aug; 126(2):399-405.
    View in: PubMed
    Score: 0.006
  21. Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status. Clin Cancer Res. 1998 Jun; 4(6):1573-9.
    View in: PubMed
    Score: 0.006
  22. Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2197-203.
    View in: PubMed
    Score: 0.005
  23. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res. 1997 Nov; 3(11):2017-24.
    View in: PubMed
    Score: 0.005
  24. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene. 1997 Aug 18; 15(8):953-60.
    View in: PubMed
    Score: 0.005
  25. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72.
    View in: PubMed
    Score: 0.005
  26. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene. 1995 May 18; 10(10):1947-54.
    View in: PubMed
    Score: 0.005
  27. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995 May 03; 87(9):682-4.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.